Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.